Hongsheng Capital

elsewhere's corpus does not cover Hongsheng Capital as a subject in its own right. The only mentions in the bundle are as a co-lead investor in two funding rounds for Methuselah (玛士撒拉), a medical-nutrition company: a Series B+ in March 2025 alongside Zhongxin Capital and Highlight Capital , and a follow-on in late 2025 with Bailian affiliates . These references come from 峰瑞资本 (FreeS Capital) family funding newsletters, not from elsewhere's own reporting or from any profile of Hongsheng Capital itself. No founding date, team, AUM, strategy, or other biographical details appear in the retrieved material.